Mold-Tek Packaging Limited (533080) Earnings Call Transcript
July 27, 2026
Earnings Call Speaker Segments
Good day, everyone, and welcome to the Mold-Tek Packaging Limited Q1 FY ’27 earnings conference call, hosted by Emkay Global Financial Services Ltd. Just a reminder that every participant line will be in listen-only mode, and you’ll have a chance to ask questions once the presentation wraps up. <<operator_script>> Please be aware that this conference is being recorded. At this point I’ll hand things over to Mr. Rajesh Kumar of Emkay Global Financial Services Ltd. Thank you, and the floor is yours, sir.
Good evening, everybody. I'd like to extend a welcome to Mr. J Lakshmana Rao, our Chairman and Managing Director, and I also want to thank him for giving us this opportunity. At this point I'll pass the call over to him so he can make the opening remarks. The floor is yours, sir.
Good afternoon, gentlemen. We really appreciate your interest in joining our quarterly results conference call. I'm pleased to share that this has been a record-setting quarter for us. Turnover went past INR300 crores, partly aided by higher raw material costs. But one of the key highlights is that EBITDA per kg has climbed to INR46.7 per kg — historically it's been around INR40, and INR42 was the best we'd seen over the past several years. So this marks a solid turnaround, driven by greater sales in pharma, food, and FMCG, which are higher value-add products, and also largely the result of the consolidation efforts we've undertaken to reduce the number of units in Hyderabad to just two, down from five previously. So this consolidation, together with better sales of high-margin products, has boosted our EBITDA margins substantially, despite the economic turmoil worldwide stemming from the war situation. So overall it's been a fairly strong quarter — even with the price hike, we managed to successfully pass the raw material price increase on to all our clients, and through internal efficiencies and consolidation, we improved our profit margins considerably. That's a brief introduction, and I hope we can go deeper during the question-and-answer session.
I’ll now hand things over to the operator.
Thank you so much. At this point we'll open things up for questions and answers. <<operator_script>> Our first question comes from Priyam Shah, who is on the line from Trinetra Asset Managers in Mumbai.
Hi sir, and thanks for taking my question. First off, over the past several years the company has branched out past decorative paints, so looking forward, what mix of revenue would you consider ideal — in other words, what share will come from outside our decorative paints over the coming few years?
Right now, by value it's 46%, but by volume, paint by itself accounts for roughly 50%, and it will probably level off around that point — or it could drop to 40% across the coming two to three years, since growth in food and FMCG and Qpack is far sharper, and pharma is far sharper, than growth in paints. So my expectation is that in three to four years, paints as a segment may account for about 40%, down from 50% at present.
And are there any other segments you’re aiming to get into?
Yes. Food is already expanding for us at this point. Food now accounts for nearly 24%, and when you factor in Qpack as well, roughly 28%, 29% of their products get sold in food. Pharma represents just 2% by weight — that's volume — but around 3.5% of overall sales. So those figures are going to rise quickly, say 40%, 50% CAGR over the coming three, four years, while food and FMCG should expand at least roughly 18%, 20% CAGR. Paint, on the other hand, may grow about 8% to 10% — right now it's 10%. At that pace, paint will gradually give up share, from 51% at present to perhaps 40% over the next three, four years in overall volumes.
Got it. And could you — all right. And could you help us get a sense of, like, what share of the incremental revenue this quarter comes from new customers, any addition?
On the new customer side, we've brought on quite a few in food and pharma — not just 1 or 2. Paint, naturally, is a market that's more matured, and we've had the leading brands with us there for several decades, I'd say. So where paint and lubes are concerned, there aren't many new additions. In food and FMCG and pharma, though, there are quite a number of clients. I can't name them all — more than 10, 20 clients will have been added this quarter.
And as a percentage, could you tell us, in food and pharma, how much has come from new customers?
On percentage terms, if you’re able to send an email, we will get back to you. It could be 3% to 5%. That said, food and FMCG growth overall comes in at 24.2%, and that is substantially stronger than what we saw across the last two, three years.
Alright. Thanks, sir.
Thanks. Our next question comes from Dipak Saha at Ashika Institutional Equities. Go ahead.
Hello. I appreciate the chance to speak. Can you hear me okay?
Yes, please go ahead.
Sir, I have a couple of questions. First, regarding volume, could you help us understand that 6% growth? Was it due to us taking a selective approach given the current market conditions? Is that why volume growth came in relatively low? And second, on the EBITDA per kg side, how sustainable is that figure? Because one part obviously is that you have come down and the mix has changed. But if you could share some color and explain what is behind this improvement in EBITDA per kg. Those are my first two questions.
Yeah. Volume growth has been somewhat affected by a decline in the lube segment. The lube segment is down 17%. That's primarily due to base oil unavailability at a couple of private companies that couldn't — because of the war in Iran, their base oil procurements were disrupted, which hit their sales and volumes and in turn hit our sales in the lube segment. So with lube making up nearly 17% to 20% of our sales, a 17% drop has had a fairly direct impact of about 3% on volume growth. So the 6% volume growth we achieved would have been 9% if lube had even stayed at the same level. So lube is a disappointing performance this quarter, and it's beyond our control because of the input problems with base oil for some of the private players. So they couldn't get the oils in time and in turn, we lost the volumes. So that's on volume growth. But I also told you last quarter that pharma growth is 38%, but it won't show up too much in volume because they're lightweight containers, lightweight components. So on the volume side, it will now — anything around 10% is a great volume growth given the war scenario.
What pleases me greatly, though, is the EBITDA improvement, which we delivered by consolidating our units, gaining better efficiencies, and enjoying somewhat stronger capacity utilization than in the prior financial year. All three of those factors are long-term in nature, and as you asked, we are bullish that we might marginally exceed our projected INR42, INR43 EBITDA for the year. Perhaps we are now targeting INR44, INR45 for the full year.
Understood, sir. So the way I'd view it is that the incremental year-over-year EBITDA per kg growth would normalize more from the INR46 we saw this quarter. Across Q2, Q3, and Q4, we'd see somewhat more normalized growth on the EBITDA per kg side versus last year. Is that the right way to look at it?
It will certainly be better than last year, since Q2 and Q3 of last year came in below INR40, but we are still targeting around INR45. The cost advantages and consolidation benefits will keep accruing, and we have other automation areas that we started recently, which will also begin contributing in a couple of quarters. So things look brighter, because the actions that have been taken are long-term in nature. Consolidating units is a one-time thing, but the benefit from it will last forever. So in that way, with the increase in food and FMCG and pharma, we are confident about sustaining momentum in the EBITDA.
Understood. One final question about the paint side. Volume rose 11% and revenue rose 30%. Regarding that 20% value growth we've locked in, could you give us some detail? Is it largely one-off, or does it look sustainable? How should we view volume and value growth going forward in paint?
No, no. The 31% increase in paint and 10% in volume is essentially offset by the surge in raw material prices. So whether this holds up will again hinge on how raw material prices move. If raw material prices level off or decline, that gap will gradually narrow. So whatever — what you should recognize is that the company was able to secure the price increase right away because of the war. Raw material jumped from the INR110 — INR105 range to nearly INR155. So the company managed to collect that money from clients within short time frames and could maintain or boost our EBITDA. Otherwise, we would have seen EBITDA hurt. So this demonstrates the relationship we have with our top clients in paint or lube or even the food industry, and also the confidence they place in Mold-Tek. So we can pass along the price increase whenever the price increase occurs and can maintain our margins, or rather improved our margins.
Understood, sir. That's genuinely useful. Thanks, and best wishes for the quarters ahead.
Thanks.
Thanks. Our next question comes from Raj Shah at Fident AMC. Go ahead, please.
Appreciate the chance to ask. My first question concerns Qpack volumes — they’ve dropped sharply, from growth near 20% in the last quarter to 2%. What caused that? And second, on pharma, on a quarter-on-quarter basis our volumes are up about 2%, 3%. How do you expect that to ramp up? And regarding our target of roughly INR55 crores of revenue from pharma, what growth do you anticipate over the next couple of quarters?
Actually, the price — the rise — sorry, the growth is just 2%, and the main reason is that Qpack is a segment that's somewhat price sensitive. Its primary use is for edible oil and cashew, and the edible oil industry has been under pressure — on one side from higher freight costs and oil prices, and on the other, with raw material prices shooting up from the INR100 level to INR150, they were rather hesitant about pushing up their sales and volumes. So that's one of the main reasons. Even the companies that had moved to our square packs have tentatively gone back to tin or other packaging formats, and that's one reason Qpack's growth is a bit disappointing. But we've now set up our Qpack facility in the North, which has started contributing numbers, and also in the South at Cheyyar. So we hope that in the coming quarters we'll see double-digit growth in Qpack once again. That covers your first question. As for the second question, in pharma we hit 41% growth, which is a sizable increase compared to last year's Q1. In volume terms too, it's 38% growth, which I'm sure you'll appreciate is a big jump given the scenario.
Right now, we already have a quarterly estimate of INR11 crores to INR12 crores, and that could rise to INR14 crores, INR15 crores by the end of the year. So we're still targeting INR50 crores, INR55 crores for our pharma, which would represent nearly 50% growth over last year's figure of INR34 crores that we achieved. So in pharma, we're definitely on a strong footing, and we also intend to move into an ophthalmic range of products, for which trial molds are finished and commercial molds might take another five to six months to come in. So hopefully, starting from the beginning of the next calendar year, we'll be entering that. And we're also examining other medical devices such as dosing pens, for which we're exploring ways to shorten the development period. But there are no firm plans as of today, though certainly that is another product we will be launching in the next financial year.
Second, regarding our finance cost, we’ve observed a steep quarter-on-quarter rise of nearly 20%. So what’s behind that? I mean, last quarter I believe we stated that we would not be adding debt from this point forward. So what caused the finance cost to go up?
The higher finance cost comes from two factors. First, as raw material prices rise, so does our need for working capital. On that, with a larger volume of material cost, we end up paying interest to the bankers. So overall working capital — the raw material cost has jumped compared with last year; the fourth quarter average price was INR97, and it is INR130. That means a jump of almost 35% in the raw material cost. So our raw material inventory cost and carrying cost will rise accordingly as well. So that is one of the main reasons the interest has gone up. It is not on account of term loans. Term loans are of course there too, but not to the extent of this much difference. This 20% rise that you see there compared with the Q4, a 20% rise, is mainly due to the cost of raw materials and goods, which shot up during the war period. So that has to be — that is the reason for the increase in finance cost.
Sir, last thing on Vibe — any news on the joint venture? I mean, when will we start seeing volumes?
So with Vibe, we've now developed 3 products for which they've filed patent applications, plus another 6 products — 3 products made up of 6 components are also moving into the pilot stage. They should likely be ready in the next 2 months as well. And together they intend to go for — they've already applied for IP on these 3 products, and 2 more products they also want to pursue IP on, and they're already making the call on IP spend and marketing efforts. They've even agreed to share in the new mold costs to the tune of $50,000. So all of this bodes well. But as I said, it's a long call. Likely around the third quarter, we'll be launching some commercial products for Vibe.
Sir, do you have any target for this year?
In the last quarter of this year, we might do a couple of crores, since these products carry very high value-add. In terms of EBITDA, they are at least equal to pharma products, if not better. So once launched, volumes can also shoot up, and next financial year we will certainly see decent numbers coming from Vibe.
Alright, thanks a lot.
Thanks. Our next question comes from CA Kaushal Sharma, calling in from Equinox Capital Venture Private Limited. Go ahead, please.
Hello there. Can you hear me okay, sir?
Yeah, we can hear you fine.
Yes. Good evening, sir. I just want to get some clarity on what you said about having passed on the prices. But when I look at your quarter-on-quarter margin and your revenue growth, revenue is up around 46.3%, while gross profit has risen only about 12% and EBITDA 16%. Given today's cost absorption, gross margin has fallen from 46.60% to 41.31%. So what's the reason for that?
No — if you look, our EBITDA has climbed 12%, and that's a really substantial leap, going from INR40.7 per kg to INR46.7 versus the prior full year. So that's quite a considerable accomplishment. On price — the revenue increase appears large owing to inflation in raw material, and we managed to recover that successfully. If we hadn't, it would have hurt our EBITDA per kg. So EBITDA per kg rose thanks to the efficiencies and the consolidation we carried out during the last financial year. Those are the reasons, and we were able to effectively pass through the raw material price increase — if you look at raw material cost, it stood at INR97 in Q4 — for the full year, INR107 in Q4, and it has become INR130 now. So revenue growth is partly attributable to inflationary raw material prices, but the real proof is EBITDA growth. So EBITDA rising by nearly INR6 against last year's figure is a big relief, or proof, that our efficiencies and consolidation are contributing to the bottom line.
All right, and could you explain the types of value-added pharmaceutical products we intend to bring to market — the ones we're planning to launch?
Yes. At the moment, our portfolio covers three product groups: bottles and caps, with a range of cap types. We have EV tubes, syringes and tubes, plus canisters. Right now we're also developing additional products, dosing pens among them, where IP requirements come into play. So we're looking to partner with appropriate IP holders who can grant us the IP rights and help bring the product into India. Doing so would shorten our development timeline from three years down to one year, letting us enter this business inside a year's time. Some imports could even be handled over this period for market seeding purposes. So in that way, we are going — sorry.
Yes, go ahead.
So that's one product where we're focusing our efforts. We're also examining semiconductor trays. That's going to be a bit of a longer-term prospect, because by the time chips and semiconductors are manufactured in India, they'll require a great deal of packaging support, and this packaging is extremely advanced — I mean, precision and high-grade raw material requirements mean a solid grasp of the technology is essential. So that's one very high value-add product we intend to explore over the coming years.
What type of retail market are we talking about?
The retail market might be quite large—perhaps INR150 to INR200. I think we still only have basic data, and that too hinges on capacity utilization, but my guess is it would be at least twice what pharma brings, because the material involved, the dimensional accuracy needed, and the temperature characteristics are all extremely demanding. It's a step beyond pharma. So worldwide, only a handful of players are doing this, with Taiwan and Korea being the primary countries. China as well, of course—there are suppliers there with solid technology. We're looking to find a strong technology partner to get into this. That one is more of a longer shot. Pens, though, is an area we're concentrating on right now, and we hope to be in that business within a year.
And sir, what sort of capacity are we allocating for these pens, and what would the ramification be?
Right now, capacity needs in India are rising sharply — not just for diabetes, but also for semaglutide and other products that are expected to shift into disposable pens. So when those volumes arrive, the volumes in this country, or even exports to African and other countries, could be sizable numbers. So we're still at the dining table stage at this point. Depending on the plans, it could be 1 million pens per month as the minimum capacity we'll start with.
And that revenue is going to land in the next financial year, correct, just as you mentioned?
Yeah, getting the validations and clearances from clients is going to take at least one year. If a tie-up comes together with a couple of clients and a couple of foreign suppliers we're working with, then probably some imports could happen this year itself. Otherwise, it'll take at least a year to get into that business.
Understood, sir. Thanks so much for taking my question.
Thanks.
Thanks. Our next question comes from Shirish Pardeshi, who is on the line from Motilal Oswal BCP.
Good evening, Mr. Rao, and thanks for giving me the chance to speak. As always, you've caught us off guard. There are just a few points I wanted to verify. Our lubes volumes came in lower this quarter, and as a result, our EBITDA has jumped to INR46.5. So what I'm hoping you can clarify, if you're able to provide a figure, is what the lube EBITDA per kg was in quarter one? And going forward, when lubes orders return, will that EBITDA come in around INR45, or will it land below that?
Lube, on its own, is a decent contributor—it averages roughly INR35 to INR40. Yes, lube prices softening isn't what's driving the EBITDA improvement. The EBITDA gain comes primarily from consolidating our units, which cut overheads, wastage, inter-unit transfers, and rejections—rejections that were happening particularly in printing, since our printing operations were split across three locations. We've now brought them together under a single roof in Sultanpur. On top of that, closing a couple of units brought overheads down substantially, from power costs all the way to supervisory and managerial staff—those people could be redeployed elsewhere, or we let some of them go. So overheads have dropped significantly, inter-unit transfers are lower, and wastage and collection rates are down as well. These are long-term in nature. That's why we're confident about consistent EBITDA growth this year despite modest volume growth. And you have to appreciate that, despite the war situation all around, every segment other than lubes performed well—pharma and food and FMCG in particular grew 38% and 24% respectively, and paint grew 10.8%, which is a fairly good number.
The only segment that's down is lubes, and that's because of base oil disruption at a couple of our clients' locations. Their dependence on the Middle East meant they couldn't secure base oil. And Qpack, as I mentioned, is a price sensitive market, of course. Edible oil and chemicals have been users, so they were a bit hesitant when raw material jumped by INR50 per kg, but they're coming back now. We're seeing that trend return, with at least a modest 10% growth expected in Q2.
Alright, so my follow-up question. In our core business, paint has expanded roughly 11%, while food and FMCG is up 26%. But there might be some distortion there, since overall volume growth in Q1 came in at around 6%. Given that setup, how should we view volume growth for the whole year, because I believe the core business will keep expanding at that pace. So I just want to get a sense of whether pricing has now settled and whether volume growth looks stronger in the second half?
Yes. On volume growth, as I mentioned previously, our target range is 10% to 12%. Even at this point, I still believe 10% is achievable, since despite the war, our clients remain very loyal to us — they're sticky — and in fact some customers who had left are returning, because they recognize that Mold-Tek has the ability to maintain the material, manufacture with good efficiency, and guarantee on-time supplies. So whenever there's disruption in the markets or the broader atmosphere, they will rely on Mold-Tek more. And the trend of IML adoption within the paint industry keeps growing, because the leader has begun using more and more IML brands. And Aditya Birla is also using more than 25%, 30% of their paints in IML. That trend is spreading to the lower players as well, and they are coming back to us. And hopefully, paint — paints in particular we will see a double-digit growth for the full year. If paint stays at that level, if lubes even return to a zero level of growth, food and pharma will lift the numbers to make sure we hit 10% volume growth at least for the year. What you should appreciate is that pharma numbers are in — weight-wise they are very less compared to pails.
So even at 10% growth, that equals 15% volume growth when pharma is expanding at 40%, and I believe the trend already aligns with that. So rather than focusing on volume alone, I'd look at — first, definitely volume; even 9% to 10% volume growth equates to 14% to 15% of last year's volume growth. And the EBITDA growth of INR5 that we achieved — actually INR6 for the — versus last year, fully at INR40.7, we delivered INR46.7, driven mainly by consolidation, efficiencies, and improved capacity utilization, all of which are long-term in nature. That's why I'm confident that this year we will exceed our target of INR42 to INR43 that we set for the full year.
All right, that's quite useful. For my final question, have we implemented any additional price hikes or handed along any raw material cost bumps during July?
Look, whatever occurs during a given month, we pass that through the following month. So in July, prices fell at the start, then rose again over the last two weeks, and as of today they're back at INR145, INR146 versus the INR155 peak they hit at the end of March. So prices are climbing once more, but we can't say whether the war will end — if it does, I'm certain they'll drop to at least INR120, INR125.
Yes, I get that. The reason I'm asking is that you also got rid of the in-house printing labels, so there's a cost lever there as well and a margin lever there as well. So I was just saying that INR46, you're saying INR43, INR44, but I would expect the margin to stay stable, at the same level of 18.5%, 19%.
That's my hope as well.
Understood. Thanks, and best of luck.
I appreciate that.
Thanks. Our next question comes from Chirag at Keynote Capital. Go ahead.
Yes. Thanks for the chance to ask. Sir, my first question has to do with the price pass-on we've been discussing. If prices go down tomorrow, would it be fair to assume that our gross profit per kg would still stay in the range of INR100?
You're seeing gross profit per kg at INR100 — where exactly is that coming from?
So if we work it out — yes, take gross profit and divide it by volume, since this whole amount is pass-on cost, correct? Suppose you're passing along — when raw material prices rise by about INR30, going from INR100 to INR130, and our selling price is INR150. Then it goes up by INR30. It's INR180 to — rising from INR150 to INR180, and because of that, at first glance the margins appear lower. But looked at on a unit economics basis, the realization is actually still better.
Yes, yes. That’s exactly why I keep urging everyone to focus on EBITDA per kg, since that’s the right indicator of profitability for the kind of business we run. Raw material is a variable outside our control, and when its price rises or falls, we pass that through to the customer the next month. So that practice continues. If prices drop tomorrow, the pass-through will drop too, and the percentage will look higher. But what really counts is the absolute number, EBITDA per kg, and that’s where we have — I’m very pleased that we achieved a jump of almost 12% versus last year’s figure, despite the war situation and despite lubes being affected because of the war. So this comes from consolidation and efficiencies that are long term and permanent in nature.
Okay, understood. Sir, regarding my second question, which concerns lubes as a segment: if I'm not mistaken, during Q2 of last year we lost a major client, and that resulted in a normalized volume rate of 1,800 to 2,000 metric tons per quarter. So one point is that this remains at a normalized level. The second thing I wanted to find out was whether, if Qpack segment volume normalizes — which saw no growth owing to the competitive intensity it faces — that is why you are now saying that EBITDA per kg, currently around INR46, will decline to roughly INR44 to INR45 as a range.
Yes. And beyond that, if capacity utilization stays flat or dips slightly, EBITDA per case will naturally decline. So I'm confident lubes will make up for it this quarter. They may not be entirely recovered, but they've improved considerably. Perhaps they arranged alternative sources for base oil. A few customers affected by the war are now returning to the market in terms of volumes, and we expect lubes to be back on track this quarter. That should, overall, lower the — I mean raise capacity utilization to the 75% level. Should that occur, we might again see a comparable EBITDA per kg. If not, there could be a slight reduction here and there. Still, the full-year projection of INR42 I provided at the close of last year will definitely be exceeded this year.
Okay, okay. Sir, the next question concerns the new lines we're entering — ophthalmic, and the plan to move into dosage pens as well. I'd like to get a sense of how large this industry is, and also, when we first entered pharma, there was the quality requirement that the plastic product must not interact with the ingredient, perhaps the capsule or something else. We ran into that problem in getting up to that quality level. In the same way, I assume this applies to dosage pens too, since there's an API — a liquid API — contained in them, correct? So I just wanted to understand the learning curve that would be needed, and as you're saying, once the IP is — once we get the IP done, the time frame can come down from three years to one year. I just wanted a ballpark view of how you're looking at this.
No, what I mean is that if we locate a partner ready to share their IP along with validation data — essentially technical support or technical understanding — then the timeline could shrink from three years down to one year itself. Because in that case, testing — some of the suppliers abroad we're already in contact with are already present in the Indian market at various stages of testing. So if we partner with them, things can move faster, like a few months or one year at most. But should that not work out and we must develop our own design and IP, then it will definitely take two to three years. So at this point, it's too early to say, but we are on track to pursue both options.
And regarding the assets of <<inaudible>>, is there any new plant and machinery for this?
No, you see, the land is already in our hands, so to begin with we'll need a minimum of 50,000 to 60,000 square feet of space, and that will come to roughly INR10 crores of investment, while the machinery for the start would also fall somewhere in the region of about INR10 crores to INR15 crores. So at minimum, a plant size of INR25 crores to INR30 crores is needed at the outset, and it has to be ramped up based on how the business grows. But the pricing and EBITDA margins are double — over double those of regular pharma products,
Right. And regarding this ophthalmic product we're discussing, can we produce it using the same assets we currently have in-house?
Right. For ophthalmic, no special safety or ambience requirements apply. Construction on 25,000 square feet is already underway at the facility we currently occupy, and that work will wrap up within six months’ time. So that’s where the ophthalmic range will be set up. The new land we acquired a year ago is going to be reserved for devices. That means mainly pens, plus some other items — there are additional devices under consideration, though it’s too early to comment on those. We’re doing feasibility work and looking at market demand. But let me assure you, Mold-Tek is now heavily focused on pharma and diagnostics, and on devices in a big way. As we move forward over the coming years — or quarters, if not quarters, then years — there will certainly be greater focus and growth in those — in that segment. It’s an area of huge potential, and we’re only touching the tip of it, so we have a long way to go.
Okay, okay. Just one final question from me, sir. Usually, once we hit 75% capacity utilization, we tend to look toward adding new capacity. Right now we're at roughly 77,000 MTPA. If you could just shed some light on what sort of…
Sixty-seven thousand, I believe. The capacity we have in total is 67,000.
Right, 67,000. So by year-end, what capacity figure are we expecting? And further out — roughly 2 or 3 years from now — how do we see things shaping up?
Sure. Each year will definitely see capacity growth of at least 10% to 12%. The aim there is to capture growth and get better utilization at three units: Cheyyar, Panipat, and Mahad. That's where our focus is right now, by broadening the product range at those sites. In Panipat, for instance, we began test marketing our thin wall products with four machines last year, and the response has been pretty good. Goods worth roughly INR70 lakhs to INR1 crore are already being sold each month, and from this month, August, we're doubling that to catch up for the festive season. So hopefully the North Panipat unit will be utilized better in food and FMCG, Qpacks. On Qpacks, we're already selling more than INR1 crores, INR1.5 crore worth of Qpacks from Panipat over these last six months. So whenever paint demand has its ups and downs, there will be fungibility with the Qpack. The same thing is being done at Cheyyar. A set of molds is now going to Cheyyar for Qpacks and that — and also paint industry molds, which will let us use the capacities in that unit better as well. So our focus now is utilizing this capacity from 75 MTPA to probably 78 or even 80 in the coming years and, apart from that, creating another 8% to 10% of capacity to catch up with the growth.
Excellent. Many thanks, sir. I will rejoin the queue.
Thanks. Our following question comes from Bhargav Buddhadev, who is on the line from Ambit Asset Management. Go ahead, please.
Yes. Good evening, everyone, and well done on a solid set of results. Sir, my first question: is it fair to say that in Paints we would have seen some volume decline, obviously because of elevated RM prices, and they might be destocking. But now that crude has come off, is it fair to say that in the quarters ahead we can see volume growth returning in paints?
On paint, we actually posted 10.8% even with the tough conditions we're seeing. Lubes are the main culprit there. That's where I mentioned the 17% decline versus Q1 of last year.
No, what I’m referring to is growth in volume.
Yes, yes. Paint volume growth is even at 10.8%. Lubes came in at minus 17%. So that's the thing—our volume growth has been somewhat stunted. If not for that, we'd have been near 9%, 9.5%. So that 17% dip in lube is what's responsible for volumes being moderately lower than they used to be. And once the war situation returns to normal—even now, I think lubes have come up with some alternative arrangements for base oil, so their sales should get back to normal. And hopefully over the coming quarters we'll also manage double-digit growth, given our growth patterns in food and Qpack, and with the Panipat and Cheyyar capacities improving, utilization improving. We're targeting double-digit growth in the quarters ahead.
Second, sir, since Asian Paints is also raising its IML share, and inside that Mold-Tek is now seeing additional business thanks to our much stronger capabilities, is it fair to expect that within Asian Paints our gross profit per kg and EBITDA per kg should rise from here on?
Yeah, yeah, it's going up since volumes have grown and capacity utilization is getting better. The molds and machines are being put to better use. I can't pick out — I mean, I can't give you the exact figure, but we've seen very good growth at Asian Paints this quarter.
And their IML share is going up — is that a fair way to put it?
Yeah, IML’s share is climbing too, and their volume growth is extremely strong — it had been lower during the prior couple of years, then turned positive starting in the last quarter, which is Q4, and this quarter has delivered one of the best growth figures.
So with paints, we saw 10% volume growth in the first quarter — and over the next nine months, that should only speed up. Is that a fair way to think about it?
At a minimum, it ought to stay in the 10% to 15% range. This time around, we're confident paint will see double-digit growth, and the signs so far are good. But if at least the war ends within a couple of months, hopefully we'll see even 15% growth become possible, thanks to very handsome growth in Asian Paint sales for us.
So you're referring to 15% for the whole year?
Pardon me?
So you're saying that for the full year, 15% in paints could be a possibility? And that's volume growth?
Somewhere in the range of 10% to 15%.
All right, that's clear. Excellent, sir — many thanks, and I wish you the very best.
Thanks.
Thanks. Our next question comes from Shaurya Yadav at Growthsphere Ventures. Go ahead.
Hi there. Can you hear me okay?
Yes.
Sir, just a single question from me. Previously, our team had been arranging some trips to China regarding a PET partnership tied to the semaglutide pen. Is there any news on that?
Yeah, we’re actually talking with a couple of them — not just one — and there may be some visits over the next few months, with discussions set to begin in September. If things go well with at least one of those parties, we could see some initiative move forward in that direction.
Alright, sir, I’ve got it.
Thanks. Our following question comes from Arnav Sakhuja at Ambit Capital. Go ahead.
Hi, thanks for taking my question. My first question is this: we saw strong volume growth of 11% in the paints sector. So could you tell us how much of that growth came from our existing clients, and how much might have come from new clients we onboarded in quarter one?
We aren't bringing any new client into paint. All of this growth comes solely from our existing clients.
And what total capex should we expect for FY ’27?
Yes. This year, our goal is to reduce it from INR130 crores, INR135 crores down to roughly INR90 crores.
Okay, and one thing you brought up during your opening remarks was that consolidating the Hyderabad facility played a big part in the EBITDA per kg improvement. So I'm wondering whether there's room to consolidate any of our other facilities, or was this the only one where we managed to pull that off?
Yes. Regarding combining units, Hyderabad is the sole site where we previously operated multiple units and have now reduced that number to 2. We cannot do the same in other places, since each of them has just 1 unit. Still, a few other areas offer room to enhance margins and efficiencies. The first is automation, through which we can cut manpower while boosting accuracy and lowering rejection rates — bringing rejections down. We are focused on this. A team is presently arranging a trip to see our partner, a good friend of ours in China, who runs comparable manufacturing facilities using highly lean manufacturing methods. That study will let us put the same approach in place here over the coming 2 quarters, and it should also lift our overall efficiencies.
All right, I appreciate you taking my questions.
Appreciate it.
Thanks. Our following question comes from Akhil Parekh at 361 Capital. Go ahead.
Yes. Thanks for the chance. And sir, congratulations on a good set of numbers. Sir, my first question is that we've seen 19% of our overall value growth, right, 6% volume growth and almost 19% growth in sales per kg. Could you break down how much of that growth comes from price inflation and how much from the product mix change?
Look, you can see straight away that the volume sold in tons rose by just 6%, 6.25%. So all the remaining part of that 18% comes mostly from higher raw material prices. It's an inflationary price increase.
Okay. But given food and FMCG, won't the product mix cause some change too?
That's right. The product mix will certainly shift, and that shift will lift net revenue per kg, since pharma is growing by 40%. Rates per kg there are considerably higher. So yes, you're right to this extent: had raw material stayed at the same level, that 25% gap would have come in at roughly 12% or 13%, because on top of 6% volume growth, the value-add in revenue would have been at least 10% to 12%, driven by the food and FMCG and pharma mix rising versus the prior quarter.
Apologies. Just to verify, the mix shift is what will drive that 12%, 13% growth, correct?
Yeah. Our volume increase has driven revenue up by a minimum of 10%. But here's what's shifting in the picture now — that 6% to 25% is largely down to inflation. At least 15% of it comes from inflation in raw material prices.
Understood. Second, sir — hearing what you said, with the way our business mix is shifting and the greater emphasis we now place on pharma, medical devices, food, and FMCG, which is also expanding more quickly: would it be reasonable to expect that from here on, overall profitability growth, or improvement in EBITDA per kg, ought to be the proper measure rather than the volume growth figure?
Yeah, I'd definitely push everyone to focus on EBITDA per kg, and naturally on volume growth as a secondary measure too, since looking ahead, volume growth may come in near 10%, while EBITDA could rise by roughly 18% to 20%, partly because of shifts in our product mix and the efficiencies we're introducing across our operations.
Okay, so is it reasonable to expect that this 19%, 20% EBITDA growth will hold up for the remainder of the year too?
Yes.
And finally, could you please provide the absolute volume and absolute sales figures for this quarter, broken out between IML and non-IML?
For this quarter, the figure comes in at roughly 75.8% when measured in tons, and 77.8% when measured by value.
That's great, sir. I really appreciate it.
Thank you. Our next question comes from Devang Mayur Bhatt at Spark PWM. Go ahead. I’d ask Mr. Devang to unmute before speaking. It appears that Devang’s line has dropped. Until then, we’ll move on to the following question. We now take a question from Chirag at Keynote Capitals. Please go ahead.
Yes, that covers everything I needed. Thanks.
Thanks. Our next question comes from Sandeep Modi, an individual investor. Go ahead.
Yes. Appreciate the chance. Sir, I had a few questions I wanted to ask. In total, how many pharma companies have come by, and how many of them are actively placing orders?
The count of pharma companies that have come to see us exceeds 50. As for orders at present, they may be arriving from roughly 20 or 25 companies. A further 10 companies are scheduled to visit us over the coming couple of weeks or months.
All right, all right, all right. Yes, sir. Just one more question. Regarding the 2.5 acres of land that we have acquired, when will construction of the building begin, and when will it become operational?
To reiterate what I mentioned, the growth we're seeing now is going to stay inside the existing facilities at our Sultanpur site — the old land — while any expansion down the road will be dedicated to devices. So it'll likely be — once a plan is in place, as I said, there are two routes for us to enter devices. The first involves partnering with someone who already holds a patent, which shortens our timeline. If we take that path, we'd need to begin right away and have the buildings finished inside 12 months, or 8 to 9 months. If instead we pursue our own internal IP and development, which takes considerably longer, that effort could begin at a later point.
Sir, are those medical devices?
Correct — things in the medical device space, such as dosing pens and comparable products.
Alright. That's great, thanks. Just one more item: what's the count of new molds currently in production for pharma and Vibe?
Look, the mold count in pharma keeps going up each quarter. For instance, I can't give you an exact figure right now, since our product count has now passed 100. Perhaps each quarter we add a minimum of five to eight new bottle or cap sizes. So annually, I believe we'll be adding no fewer than 15 to 20 products — either in different sizes, or within a given size, with varying weights and neck dimensions.
Alright. Sir, is there any positive update regarding pharmaceuticals and semiconductor packaging?
Yeah, plenty is going on behind the scenes, and in a few months or so, we should be able to discuss it.
And, sir, do you have any capital expenditure figure for 2027?
Right, for this current year capex should come to roughly INR90 crores, assuming INR25 crores to INR30 crores goes to pharma and the rest covers balancing and replacement.
All right, so is the medical device the only new business we're getting into, or are there other businesses we're also planning?
White goods are something we would be open to looking at. Electronics and semiconductor packing are also on our radar. All of those are long shots. Right now they're at the drawing board stage, and the time frames will be decided based on how we tie things up or how we bring partners into this field.
All right. And sir, regarding those 5 to 2 units that we've consolidated — so at this point, with the other 3 units, what business is happening in them right now?
Right now, those lands are available to us. Probably in a year or two, when a good price comes along, we may sell at least a couple of them and use the funds.
Alright, thanks a lot, sir.
Thanks. Our next question comes from Devang Mayur Bhatt at Spark PWM. Go ahead.
Thanks. I appreciate you taking my question. So what I was asking is this: how much did EBITDA per kg gain because of the better realization?
When you combine FMCG and pharma at a higher realization level, that should give us at least INR3 per kg from those two lines, plus another INR3 coming from consolidation and better efficiencies — improved efficiencies.
All right. And given that our RM cost — RM is going to be higher in the near term — so what's your outlook for working capital?
Yeah, that was one of the questions. That's the reason interest has risen quite a bit. With raw material costs higher and inventory costs up, we end up paying more for working capital — we're using more working capital, so we pay more interest on it. So right now working capital stands at 100 — INR125 crores, versus roughly INR110 crores, INR112 crores at the end of March, I believe. So it's increased by about INR16 crores, INR18 crores.
So you’re expecting that to keep going in FY ’27?
There’s a chance it levels off at that point, since raw material isn’t as costly now as it was at the end of March. At present it’s trading at roughly 10% below the peak-month level. So with luck it will hold there. It might not fall by much, yet it won’t rise. It could drop to a level of 5%, 10%, but an increase seems unlikely given where raw material prices stand. Should the war get worse and crude prices climb further, that would be a different situation. Still, under the current circumstances, it appears it will ease somewhat.
And how much did you spend on capex during Q1 FY ’27?
In Q1, we've already put in INR20 crores — I believe it's INR20 crores, INR22 crores.
Alright. Thank you. That covers everything on my side.
Thanks. Our following question comes from Dhruvin Doshi at NV Alpha. Go ahead.
Yes. Hello, sir. Thank you for the chance. Sir, you said raw material cost jumped from INR107 per kg blended in Q4 ’26 to roughly INR130-ish in the first quarter of ’27, if I heard that correctly. Sir, I just wanted to check whether we had any inventory gains in the gross margin of, say, INR103 per kg versus INR97 last quarter?
There will be some inventory gains, though they won't be huge.
Could you put a number on that, say INR2 or INR1 per kg?
Most likely, yes — you could put it at INR1 to INR1.50.
Got it, sir. And sir, what did you say the raw material cost is right now?
Right now the raw material sits at INR145. I believe the peak hit INR160 around the end of March or the start of April.
All right, sir, I've got it. That's all I have to say, sir. Many thanks.
Thanks. Our following question comes from Amit Kumar at Determined Investment — please go ahead.
Yes, hello there. Am I coming through okay?
Yes, yes.
Sir, just one question. What are your suppliers saying about raw material availability? Because again, all through this month — July — the Strait of Hormuz was open for only about 15, 20 days, and now we understand that the U.S. Congress and Senate have also sort of passed the bill that will restrict imports of Russian crude oil into the global market as well. So have you had any kind of conversation, or have your suppliers had any kind of conversations with you, regarding supply availability?
On supply availability, their concern isn't there—it's pricing where they can't get comfortable. That volatility is going to persist. As things stand right now, PP—that's copolymer, our primary raw material—is still, well, I won't claim there's an abundance, but as of today you can get it. Even during the roughest stretch in March and April, the material could be sourced; there was a bit of a shortage and some scrambling to obtain it from Reliance or other producers. That said, I'd say conditions today are improved relative to March-April where availability is concerned. On the pricing side, certainly, it tracks crude; whatever price they're paying for crude gets passed through, up or down. So that volatility remains, but on the availability front we're in a much stronger position today than three months back.
On the inventory side — both what you're holding yourselves and what your customers are holding — it's kind of below typical levels, or above typical levels. So how should we think about where things roughly are right now, if you have any read on that at all?
We lack specifics on our customers or competitors, though our benchmarks sit at roughly one month of inventory — three weeks to one month.
Is that regarding raw materials or finished goods?
I mean raw material. When you add finished goods and SFG, it’s probably 1 month plus a few days.
All right, I’ve got it. Thanks. That’s all I have to say.
Thanks. Ladies and gentlemen, we’ll treat that as today’s final question, and at this point we’d like to pass the conference back to management for closing remarks. Sir, the floor is yours.
I want to use this chance to thank the Emkay team for setting up this meeting with all the investors who have demonstrated a great deal of interest in our company and its operations. I thank each and every one of you, and I wish you a wonderful evening. Bye. Thank you, Rajesh.
<<operator_signoff>>
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Mold-Tek Packaging Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Mold-Tek Packaging Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.